StockNews.com Begins Coverage on Sorrento Therapeutics (NASDAQ:SRNE)

StockNews.com began coverage on shares of Sorrento Therapeutics (NASDAQ:SRNE – Free Report) in a research report report published on Wednesday. The brokerage issued a hold rating on the biopharmaceutical company’s stock. Sorrento Therapeutics Stock Performance SRNE opened at $0.04 on Wednesday. The company has a debt-to-equity ratio of 0.14, a current ratio of 0.88 and […]

Leave a Reply

Your email address will not be published.

Previous post Benchmark Increases PDD (NASDAQ:PDD) Price Target to $190.00
Next post No more waiting list — for now — as Chicago Cubs make season tickets available for immediate purchase